Anti-Brain Derived Neurotrophic Factor Antibody

Recombinant Human Brain Derived Neurotrophic Factor (BDNF).

Anti-Brain Derived Neurotrophic Factor Antibody detects level of Brain Derived Neurotrophic Factor & has been published & validated for use in ELISA, WB, IH.

Immunohistochemistry: 5-10μg/mL (see suggested protocol).

Immunoblotting: 5-10μg/mL. BDNF is not easily extracted in standard buffers. Dissected tissues should be homogenized in 10 volumes of 100mM phosphate buffer containing 1mM EDTA, 2M guanidine hydrochloride (pH7.2), and three protease inhibitors, 10mM N-ethylmaleimide, 0.36mM pepstatin, and 1mM PMSF. Homogenates are then sonicated and centrifuged at 46K x g for 30 minutes at 4C. BDNF migrates as 18kDa, with a homodimer at ~27-30kDa. 1:1,000

ELISA: 5-10μg/mL

BIOLOGICAL ACTIVITY: Neutralizes BDNF, but not other neurotrophins.



Optimal working dilutions must be determined by end user.

Research Category
Neuroscience

Research Sub Category
Neurochemistry & Neurotrophins

Neuroinflammation & Pain

Brain Derived Neurotrophic Factor (BDNF). By dot blot, less than 1% cross-reactivity against NGF, NT3 or NT4.

Format: Purified

Immunoglobulin fraction lyophilized from PBS, with no preservatives. Reconstitute with 500 μL of sterile distilled water (1 mg/mL).

Maintain lyophilized material at -20 to -70°C for up to one year after date of receipt. After reconstitution maintain at -20 to -70°C in undiluted aliquots for up to six months. Glycerol (ACS grade or better) can be added (1:1) for additional stability.

Replaces: AB1534P

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.